A new CT scanner from Toshiba America Medical Systems has received 510(k) clearance from the Food and Drug Administration. The system, called Asteion, is a subsecond scanner, and Toshiba has positioned it just below the Tustin, CA, vendor's new Aquilion
A new CT scanner from Toshiba America Medical Systems has received 510(k) clearance from the Food and Drug Administration. The system, called Asteion, is a subsecond scanner, and Toshiba has positioned it just below the Tustin, CA, vendor's new Aquilion half-second CT unit (SCAN 9/16/98). Toshiba will introduce Asteion at the upcoming Radiological Society of North America meeting.
Asteion features a 0.75-second rotation speed and solid-state detectors, according to Charles Corogenes, director of the CT business unit at TAMS. The system will carry a 4-million-heat-unit HeliCool x-ray tube and a 48-kW generator. It has a similar graphical user interface to the Aquilion scanner. It will also come standard with Aspire CI, Toshiba's CT fluoroscopy package. Asteion shipments will begin in January, Corogenes said.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.